Patents by Inventor James Hnatyszyn

James Hnatyszyn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220041737
    Abstract: This application relates to uses of antibodies against fibroblast growth factor receptor 2 (FGFR2), including antibodies against the FGFR2 isoform FGFR2-IIIb (also known as FGFR2b), in treatment of certain cancers in combinations with mFOLFOX6 chemotherapy.
    Type: Application
    Filed: July 2, 2021
    Publication date: February 10, 2022
    Applicant: Five Prime Therapeutics, Inc.
    Inventors: Helen L. Collins, James Hnatyszyn, Hong Xiang, Xiang Zhang
  • Patent number: 11091555
    Abstract: This application relates to uses of antibodies against fibroblast growth factor receptor 2 (FGFR2), including antibodies against the FGFR2 isoform FGFR2-IIIb (also known as FGFR2b), in treatment of certain cancers in combinations with mFOLFOX6 chemotherapy.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: August 17, 2021
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Helen L. Collins, James Hnatyszyn, Hong Xiang, Xiang Zhang
  • Publication number: 20200079856
    Abstract: This application relates to uses of antibodies against fibroblast growth factor receptor 2 (FGFR2), including antibodies against the FGFR2 isoform FGFR2-IIIb (also known as FGFR2b), in treatment of certain cancers in combinations with mFOLFOX6 chemotherapy.
    Type: Application
    Filed: May 15, 2018
    Publication date: March 12, 2020
    Applicant: Five Prime Therapeutics, Inc.
    Inventors: Helen L. Collins, James Hnatyszyn, Hong Xiang, Xiang Zhang
  • Patent number: 10145852
    Abstract: Disclosed herein are methods and systems for detecting CD3 and CD16 in the same sample of a colorectal, head & neck, or lung tumor using immunohistochemical methods using primary antibodies from the same host species and secondary antibodies immunoreactive with antibodies of the host species of the primary antibodies. Methods to denature and block the first primary antibody contacted with the sample are provided.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: December 4, 2018
    Assignee: VENTANA MEDICAL SYSTEMS, INC.
    Inventors: Jacquelyn Smith, Harry James Hnatyszyn, Erik Olson, Noah Theiss, Alton Yates, Eric Kaldjian, Bharathi Vennapusa
  • Publication number: 20180340870
    Abstract: Systems and methods for selecting therapeutic agents for cancers using next generation sequencing, automated dissection, and/or automated slide stainers are disclosed. Non-responsive regions of a tumor sample having a heterogenous staining pattern for a predictive biomarker are excised using an automated dissection tool. Mutations linked to additional predictive biomarkers are identified in the excised portion of the sample by next generation sequencing. The relevance of the additional predictive biomarker(s) is confirmed by histochemical staining. Therapeutic courses may then be selected on the basis of the staining patterns of the predictive biomarkers.
    Type: Application
    Filed: July 26, 2018
    Publication date: November 29, 2018
    Inventors: Heather Gustafson, Harry James Hnatyszyn
  • Publication number: 20180106816
    Abstract: Disclosed herein are methods and systems for detecting CD3 and CD16 in the same sample of a colorectal, head & neck, or lung tumor using immunohistochemical methods using primary antibodies from the same host species and secondary antibodies immunoreactive with antibodies of the host species of the primary antibodies. Methods to denature and block the first primary antibody contacted with the sample are provided.
    Type: Application
    Filed: December 14, 2017
    Publication date: April 19, 2018
    Inventors: Jacquelyn Smith, Harry James Hnatyszyn, Erik Olson, Noah Theiss, Alton Yates, Eric Kaldjian, Bharathi Vennapusa
  • Patent number: 9874571
    Abstract: Disclosed herein are methods and systems for detecting two different epitopes in the same sample using immunohistochemical methods using primary antibodies from the same host species and secondary antibodies immunoreactive with antibodies of the host species of the primary antibodies. Methods to denature and block the first primary antibody contacted with the sample are provided.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: January 23, 2018
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Jacquelyn Smith, Harry James Hnatyszyn, Erik Olson, Noah Theiss, Alton Yates, Eric Kaldjian, Bharathi Vennapusa
  • Publication number: 20170234886
    Abstract: Disclosed herein are methods and systems for detecting two different epitopes in the same sample using immunohistochemical methods using primary antibodies from the same host species and secondary antibodies immunoreactive with antibodies of the host species of the primary antibodies. Methods to denature and block the first primary antibody contacted with the sample are provided.
    Type: Application
    Filed: May 2, 2017
    Publication date: August 17, 2017
    Inventors: Jacquelyn Smith, Harry James Hnatyszyn, Erik Olson, Noah Theiss, Alton Yates, Eric Kaldjian, Bharathi Vennapusa
  • Patent number: 9719137
    Abstract: The present invention relates to amplification primers with a universal tag and sequencing primers comprising at least one non-natural nucleobase capable of hybridizing to a complementary non-natural nucleobase. The present invention further relates to amplification methods of nucleic acid amplification and sequencing using an amplification primer with a universal tag and sequencing primers, as well as kits and solid supports comprising such primers and tags.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: August 1, 2017
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Thomas Battersby, Toumy Guettouche, James Hnatyszyn
  • Patent number: 9689875
    Abstract: The present application provides methods and systems for detecting both CD3 and CD16 in a sample using immunohistochemical methods, for example when the primary antibodies for CD3 and CD16 are from the same species (e.g., both rabbit antibodies). Methods to denature and block the first primary antibody contacted with the sample are provided.
    Type: Grant
    Filed: August 21, 2014
    Date of Patent: June 27, 2017
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Jacquelyn Smith, Harry James Hnatyszyn, Erik Olson, Noah Theiss, Alton Yates, Eric Kaldjian, Bharathi Vennapusa
  • Publication number: 20160304951
    Abstract: The present invention relates to amplification primers with a universal tag and sequencing primers comprising at least one non-natural nucleobase capable of hybridizing to a complementary non-natural nucleobase. The present invention further relates to amplification methods of nucleic acid amplification and sequencing using an amplification primer with a universal tag and sequencing primers, as well as kits and solid supports comprising such primers and tags.
    Type: Application
    Filed: June 29, 2016
    Publication date: October 20, 2016
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventors: Thomas Battersby, Toumy Guettouche, James Hnatyszyn
  • Publication number: 20160231322
    Abstract: The present application provides methods and systems for detecting both CD3 and CD16 in a sample using immunohistochemical methods, for example when the primary antibodies for CD3 and CD16 are from the same species (e.g., both rabbit antibodies). Methods to denature and block the first primary antibody contacted with the sample are provided.
    Type: Application
    Filed: August 21, 2014
    Publication date: August 11, 2016
    Inventors: Jacquelyn Smith, Harry James Hnatyszyn, Erik Olson, Noah Theiss, Alton Yates, Eric Kaldjian, Bharathi Vennapusa
  • Patent number: 9404154
    Abstract: The present invention relates to amplification primers with a universal tag and sequencing primers comprising at least one non-natural nucleobase capable of hybridizing to a complementary non-natural nucleobase. The present invention further relates to amplification methods of nucleic acid amplification and sequencing using an amplification primer with a universal tag and sequencing primers, as well as kits and solid supports comprising such primers and tags.
    Type: Grant
    Filed: August 13, 2014
    Date of Patent: August 2, 2016
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Thomas Battersby, Toumy Guettouche, James Hnatyszyn
  • Publication number: 20140377755
    Abstract: The present invention relates to amplification primers with a universal tag and sequencing primers comprising at least one non-natural nucleobase capable of hybridizing to a complementary non-natural nucleobase. The present invention further relates to amplification methods of nucleic acid amplification and sequencing using an amplification primer with a universal tag and sequencing primers, as well as kits and solid supports comprising such primers and tags.
    Type: Application
    Filed: August 13, 2014
    Publication date: December 25, 2014
    Applicant: SIEMENS HEALTHCARE DIAGNOSTICS INC.
    Inventors: Thomas Battersby, Toumy Guettouche, James Hnatyszyn
  • Patent number: 8735063
    Abstract: The present invention is directed to methods and reagents for determining the genotype of a hepatitis C virus (HCV) species present in a test sample. The invention more particularly relates to mixtures of degenerate amplification and sequencing primers, and methods of using such primers, that are complementary to a plurality of HCV species, and are capable of generating nucleotide sequence information for a region of NS5B of HCV that is, for each species, indicative of the type and/or subtype, of the species present in the sample.
    Type: Grant
    Filed: October 30, 2009
    Date of Patent: May 27, 2014
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Marcellinus Beld, Remko Gouw, Toumy Guettouche, James Hnatyszyn, Carola van der Meer
  • Publication number: 20120142004
    Abstract: The present invention relates to amplification primers with a universal tag and sequencing primers comprising at least one non-natural nucleobase capable of hybridizing to a complementary non-natural nucleobase. The present invention further relates to amplification methods of nucleic acid amplification and sequencing using an amplification primer with a universal tag and sequencing primers, as well as kits and solid supports comprising such primers and tags.
    Type: Application
    Filed: May 19, 2010
    Publication date: June 7, 2012
    Applicant: SIEMENS HEALTHCARE DIAGNOSTICS INC.
    Inventors: Thomas Battersby, Toumy Guettouche, James Hnatyszyn
  • Publication number: 20110123441
    Abstract: The generation and validation of a novel monoclonal GREB1 antibody (GREB1ab). Methods for the prognosis, diagnosis, assessment of disease progression, severity and outcome utilize GREB1 molecules as biomarkers. The GREB1 antibody is also a useful tool for investigations focused on the expression, distribution and function of GREB1 in normal and cancer tissues.
    Type: Application
    Filed: October 20, 2010
    Publication date: May 26, 2011
    Applicants: UNIVERSITY OF MIAMI, THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Marc E. Lippman, Harry James Hnatyszyn, Mingli Liu, James M. Rae
  • Publication number: 20100196876
    Abstract: The present invention is directed to methods and reagents for determining the genotype of a hepatitis C virus (HCV) species present in a test sample. The invention more particularly relates to mixtures of degenerate amplification and sequencing primers, and methods of using such primers, that are complementary to a plurality of HCV species, and are capable of generating nucleotide sequence information for a region of NS5B of HCV that is, for each species, indicative of the type and/or subtype, of the species present in the sample.
    Type: Application
    Filed: October 30, 2009
    Publication date: August 5, 2010
    Applicant: SIEMENS HEALTHCARE DIAGNOSTICS INC.
    Inventors: James Hnatyszyn, Marcellinus Beld, Toumy Guettouche, Remko Gouw, Carola van der Meer
  • Publication number: 20070259339
    Abstract: The present invention is directed to methods and reagents for determining the genotype of a hepatitis C virus (HCV) species present in a test sample. The invention more particularly relates to mixtures of degenerate amplification and sequencing primers, and methods of using such primers, that are complementary to a plurality of HCV species, and are capable of generating nucleotide sequence information for a region of NS5B of HCV that is, for each species, indicative of the type and/or subtype, of the species present in the sample.
    Type: Application
    Filed: December 22, 2006
    Publication date: November 8, 2007
    Inventors: James Hnatyszyn, Marcellinus Beld, Toumy Guettouche, Remko Gouw, Carola van der Meer
  • Patent number: 7285282
    Abstract: An isolated peptide or polypeptide containing the sequence VSIGLSFPMLP (SEQ ID NO:1), found in the secreted form of human MUC1, that enhances an immune response when administered to a mammal, compositions containing the peptide, host cells producing the peptide and methods of use. The peptide or polypeptide may be conjugated to a carrier protein and administered as part of a vaccine or immunogenic composition for prevention or treatment of a disease or disorder.
    Type: Grant
    Filed: April 2, 2002
    Date of Patent: October 23, 2007
    Assignee: University of Miami
    Inventors: Diana M. Lopez, Lynn M. Herbert, Mantley Dorsey, Jr., Günter Kraus, H. James Hnatyszyn